Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 1
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer death, and accounts for 5.6% of all cancers. Nearly 82% of the approximately 550,000 liver cancer deaths each year occur in Asia. In some regions, cancer-related death from HCC is second only to lung cancer. The incidence and mortality of HCC are increasing in America countries as a result of an ageing cohort infected with chronic hepatitis C, and are expected to continue to rise as a consequence of the obesity epidemic. Clinical care and survival for patients with HCC has advanced considerably during the last two decades, thanks to improvements in patient stratification, an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and the introduction of novel therapies and strategies in prevention. Nevertheless, HCC remains the third most common cause of cancer-related deaths worldwide. These LAASL recommendations on treatment of hepatocellular carcinoma are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with liver cancer.
Authors and Affiliations
Nahum Méndez-Sánchez, Ezequiel Ridruejo, Angelo Alves de Mattos, Norberto C. Chávez-Tapia, Rodrigo Zapata, Raymundo Paraná, Ricardo Mastai, Edna Strauss, Luis Gonzalo Guevara -Casallas, Jorge Daruich, Adrian Gadano, Edison Roberto Parise, Misael Uribe, Nancy E. Aguilar-Olivos, Lucy Dagher, Ben-Hur Ferraz-Neto, Martha Valdés-Sánchez, Juan F. Sánchez-Avila
Keywords
Related Articles
- EP ID EP78429
- DOI -
- Views 119
- Downloads 0
Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients
[b]Background[/b]. Several noninvasive predictive models were developed to substitute liver biopsy for fibrosis assessment. [b]Aim[/b]. To evaluate the diagnostic value of fibronectin which reflect extracellular matrix m...
Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease
Alcoholic liver disease (ALD) is a definition encompassing a spectrum of disorders ranging from simple steatosis to cirrhosis and hepatocellular carcinoma. Excessive alcohol consumption triggers a series of metabolic rea...
Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital
Introduction. Few studies have evaluated the factors involved in the spontaneous HBsAg seroclearance in patients with chronic hepatitis B (HBV) followed up on a long-term basis from areas with a low prevalence of HBV inf...
The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population
Background. Nonalcoholic fatty liver disease (NAFLD) encompasses: fatty liver (SS), steatohepatitis (NASH) with or without fibrosis and cirrhosis. Patatine-like phosphatas in domain 3 (PNPLA3; adiponutrin; SNP rs738409 C...
Common SPINK-1 mutations do not predispose to the development of non-alcoholic fatty liver disease
Background: Non-alcoholic fatty liver disease (NAFLD) is common in obese and diabetics. Serine protease inhibitor Kazal-1 (SPINK-1) protein is highly expressed in the liver and adipose tissue of diabetic and obese sugges...